| Primary | Number of Participants With Hospitalization for Heart Failure (HHF), Broad + Specific Definition | Number of participants with Hospitalization for Heart Failure (HHF), using broad + specific HHF definition. HHF - broad defined as any diagnosis associated with healthcare encounters, including hospitalizations and specialist outpatient and primary care encounters, or dispensation or any other record of the high-ceiling diuretics (loop diuretics). HHF - specific defined as a primary diagnosis associated with hospital admission. For HHF - broad + specific, HHF-specific definition was used unless only broad definition were available. However, for Japan South Korea and Taiwan, both definitions were available, but broad definition was used. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. | | OG002 | Empagliflozin (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, identified from secondary data sources from 11 countries. New users of empagliflozin were matched to new users of DPP-4i using a propensity score (PS)-matching approach. | | OG003 | DPP-4i (Matched to Empagliflozin) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) between May 2014 and December 2019, identified from secondary data sources from 11 countries. DPP-4 users were matched to new users of empagliflozin, using a 1:1 propensity score matching approach. |
| | Units | Counts |
|---|
| Participants | - OG000163812
- OG001163812
- OG00285244
- OG003
|
| | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0001395
- OG0012043
- OG002765
- OG003
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Cox proportional hazard model | Cox proportional hazard model adjusted for unbalanced propensity score (PS)-variables at baseline. | <0.005 | | Adjusted Hazard Ratio | 0.70 | | | 2-Sided | 95 | 0.60 | 0.83 | | | | | Other | | | | |
|
| Primary | Number of Participants With Hospitalization for Heart Failure (HHF), Broad Definition | Reported is the number of participants with hospitalization for heart failure (HHF), using broad definition of HHF. HHF - broad is defined as any diagnosis associated with healthcare encounters, including hospitalizations and specialist outpatient and primary care encounters, or dispensation or any other record of the high-ceiling diuretics (loop diuretics). | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) |
|
| Primary | Number of Participants With Hospitalization for Heart Failure (HHF), Specific Definition | Reported is the number of participants with hospitalization for heart failure, using specific definition for HHF. HHF - specific defined as a primary diagnosis associated with hospital admission. | Patients, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) |
|
| Primary | Number of Participants With All-cause Mortality (ACM) | Number of participants with all-cause mortality (ACM). | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Primary | Number of Participants With Composite Outcome, Including Hospitalization for Heart Failure (HHF) and All Cause Mortality (ACM) | Number of participants with composite outcome, including hospitalization for heart failure (HHF) and all cause mortality (ACM). | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Primary | Number of Participants With Composite Outcome, Including Myocardial Infraction (MI), Stroke and All Cause Mortality (ACM) | Number of participants with composite outcome, including myocardial infraction (MI), stroke and all cause mortality (ACM). | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Primary | Number of Participants With Myocardial Infarction (MI) | Number of participants with myocardial infarction (MI). | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Primary | Number of Participants With Stroke | Number of participants with stroke. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With Cardiovascular Mortality (CM) | Number of participants with cardiovascular mortality (CM). | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With Composite Outcome Including Hospitalization for Heart Failure (HHF) and Cardiovascular (CV) Mortality | Number of participants with composite outcome including hospitalization for heart failure (HHF) and cardiovascular (CV) mortality. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With 3-point Major Adverse Cardiovascular (CV) Events (MACE), Defined as a Composite Outcome Including Myocardial Infarction (MI), Stroke and Cardiovascular (CV) Mortality | Number of participants with 3-point major adverse cardiovascular (CV) events (MACE), defined as a composite outcome including myocardial infarction (MI), stroke and cardiovascular (CV) mortality. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | |
|
| Secondary | Number of Participants With Coronary Revascularization Procedure | Number of participants with coronary revascularization procedure. | Patients, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With End-stage Renal Disease (ESRD) | Number of participants with end-stage renal disease (ESRD). | Patients, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With Estimated Glomerular Filtration Rate (eGFR) Decline | Number of participants with estimated glomerular filtration rate (eGFR) decline. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With Progression From Normoalbuminuria to Micro- or Macroalbuminuria | Number of participants with progression from normoalbuminuria to micro- or macroalbuminuria. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With Composite Outcome Including eGFR Decline and Progression to Micro- or Macroalbuminuria | Number of participants with composite outcome including Estimated glomerular filtration rate (eGFR) decline and progression to micro- or macroalbuminuria. | All patients included in the study, who were either new user of any SGLT-2i (incl. empagliflozin) or DPP-4i. Results are reported by 1:1 PS-matched cohorts of SGLT-2i/DPP-4i and empagliflozin/DPP-4i. Arms are not mutually exclusive. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i. | | | | ID | Title | Description |
|---|
| OG000 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. |
|
| Secondary | Number of Participants With Bone Fracture | Number of participants with bone fracture. Data for this endpoint was only collected and analyzed for the matched cohort of empagliflozin/DPP-4i. | Only patients in the study, who were included in the 1:1 propensity-score matched cohort of empagliflozin/DPP-4i. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, identified from secondary data sources from 11 countries. New users of empagliflozin were matched to new users of DPP-4i using a propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to Empagliflozin) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) between May 2014 and December 2019, identified from secondary data sources from 11 countries. DPP-4 users were matched to new users of empagliflozin, using a 1:1 propensity score matching approach. |
| |
| Secondary | Number of Participants With Diabetic Ketoacidosis | Number of participants with diabetic ketoacidosis. Data for this endpoint was only collected and analyzed for the matched cohort of empagliflozin/DPP-4i | Only patients in the study, who were included in the 1:1 propensity-score matched cohort of empagliflozin/DPP-4i. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, identified from secondary data sources from 11 countries. New users of empagliflozin were matched to new users of DPP-4i using a propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to Empagliflozin) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) between May 2014 and December 2019, identified from secondary data sources from eleven countries. DPP-4 users were matched to new users of empagliflozin, using a 1:1 propensity score matching approach. |
| |
| Secondary | Number of Participants With Severe Hypoglycemia | Number of participants with severe hypoglycemia. Data for this endpoint was only collected and analyzed for the matched cohort of empagliflozin/DPP-4i. | Only patients in the study, who were included in the 1:1 propensity-score matched cohort of empagliflozin/DPP-4i. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, identified from secondary data sources from 11 countries. New users of empagliflozin were matched to new users of DPP-4i using a propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to Empagliflozin) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) between May 2014 and December 2019, identified from secondary data sources from eleven countries. DPP-4 users were matched to new users of empagliflozin, using a 1:1 propensity score matching approach. |
| |
| Secondary | Number of Participants With Lower-limb Amputation | Number of participants with lower-limb amputation. Data for this endpoint was only collected and analyzed for the matched cohort of empagliflozin/DPP-4i. | Only patients in the study, who were included in the 1:1 propensity-score matched cohort of empagliflozin/DPP-4i. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, identified from secondary data sources from 11 countries. New users of empagliflozin were matched to new users of DPP-4i using a propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to Empagliflozin) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) between May 2014 and December 2019, identified from secondary data sources from 11 countries. DPP-4 users were matched to new users of empagliflozin, using a 1:1 propensity score matching approach. |
| |
| Secondary | Number of Participants With Acute Kidney Injury Requiring Dialysis | Number of participants with acute kidney injury requiring dialysis. Data for this endpoint was only collected and analyzed for the matched cohort of empagliflozin/DPP-4i. | Only patients in the study, who were included in the 1:1 propensity-score matched cohort of empagliflozin/DPP-4i. Country-level results are reported and only include countries with non-missing data or a sufficient number of events to satisfy local patient privacy regulations. | Posted | | Count of Participants | | Participants | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, identified from secondary data sources from 11 countries. New users of empagliflozin were matched to new users of DPP-4i using a propensity score (PS)-matching approach. | | OG001 | DPP-4i (Matched to Empagliflozin) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) between May 2014 and December 2019, identified from secondary data sources from 11 countries. DPP-4 users were matched to new users of empagliflozin, using a 1:1 propensity score matching approach. |
| |
| Secondary | Healthcare Resource Utilization (HCRU): Number of Any Medical Visit | HCRU data were collected from seven of the 11 participating countries including Finland, Japan, South Korea, Norway, Spain, Sweden, and Taiwan. Outcomes captured as HCRU include emergency room visits, first inpatient stay, all-cause hospital admissions and outpatient healthcare visits. HCRU outcomes were investigated for the matched cohort of empagliflozin/DPP-4 only. Due to possibly huge differences in healthcare systems and local practices, HCRU outcomes were presented descriptively by country as per prespecified analysis plan. For arms with 0 patients analyzed, no data was collected for the specific outcome in this country. | Only patients in the study, who were included in the matched cohort of empagliflozin/DPP-4i from the following seven countries: Finland, Japan, South Korea, Norway, Spain, Sweden or Taiwan. HCRU outcomes are presented descriptively by country as per prespecified analysis plan. For arms with 0 patients analyzed, no data was collected for the specific outcome in this country. | Posted | | Number | | Visit | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4) - Finland | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019. Empagliflozin users were matched to incident users of (dipeptidyl peptidase-4) DPP-4 using a 1:1 propensity score matching approach. Only finish patients are included in this group. | | OG001 | DPP-4 (Matched to Empagliflozin) - Finland |
|
| Secondary | Healthcare Resource Utilization (HCRU): Number of Any Prescription | HCRU data were collected from seven of the 11 participating countries including Finland, Japan, South Korea, Norway, Spain, Sweden, and Taiwan. Outcomes captured as HCRU include pharmacy dispensations/prescriptions of different antidiabetic drugs, different drugs and prescriptions. HCRU outcomes were investigated for the matched cohort of empagliflozin/DPP-4 only. Due to possibly huge differences in healthcare systems and local practices, HCRU outcomes were presented descriptively by country as per prespecified analysis plan. For arms with 0 patients analyzed, no data was collected for the specific outcome in this country. | Only patients in the study, who were included in the matched cohort of empagliflozin/DPP-4i from the following seven countries: Finland, Japan, South Korea, Norway, Spain, Sweden or Taiwan. HCRU outcomes are presented descriptively by country as per prespecified analysis plan. For arms with 0 patients analyzed, no data was collected for the specific outcome in this country. | Posted | | Number | | Prescription | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4) - Finland | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019. Empagliflozin users were matched to incident users of (dipeptidyl peptidase-4) DPP-4 using a 1:1 propensity score matching approach. Only finish patients are included in this group. | | OG001 | DPP-4 (Matched to Empagliflozin) - Finland |
|
| Secondary | Total Healthcare Costs - Finland, Norway, Sweden | Total healthcare cost include costs for emergency room visits, first inpatient stay, all-cause hospital admissions, outpatient healthcare visits and pharmacy dispensations/prescriptions of different antidiabetic drugs, different drugs and prescriptions. Total healthcare costs for Finland, Norway and Sweden are reported in Euro per year. Due to possible huge differences in healthcare systems, cost of care outcomes are presented by country as prespecified in the analysis plan. | Only patients who were included in the matched cohort of empagliflozin/DPP-4i from Finland, Norway and Sweden. Cost are presented descriptively by country as per prespecified analysis plan. | Posted | | Median | Inter-Quartile Range | Euro per year | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4) - Finland | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019. Empagliflozin users were matched to incident users of (dipeptidyl peptidase-4) DPP-4 using a 1:1 propensity score matching approach. Only finish patients are included in this group. | | OG001 | DPP-4 (Matched to Empagliflozin) - Finland | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 (DPP-4) between May 2014 and December 2019, in all countries included in this study. DPP-4 users were matched to incident users of empagliflozin, using a 1:1 propensity score matching approach. Only finish patients are included in this arm |
|
| Secondary | Total Healthcare Cost - Japan | Total healthcare costs include costs for emergency room visits, first inpatient stay, all-cause hospital admissions, outpatient healthcare visits and pharmacy dispensations/prescriptions of different antidiabetic drugs, different drugs and prescriptions. Total healthcare cost for Japan are reported in Japanese Yen (JPY) per year. Due to possible huge differences in healthcare systems, cost of care outcomes are presented by country as prespecified in the analysis plan. | Only patients who were included in the matched cohort of empagliflozin/DPP-4i from Japan. Costs are presented descriptively by country as per prespecified analysis plan. | Posted | | Median | Inter-Quartile Range | JPY per year | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4) - Japan | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, in all countries included in this study. Empagliflozin users were matched to incident users of (dipeptidyl peptidase-4) DPP-4 using a 1:1 propensity score matching approach. Only japanese patients are included in this arm. | | OG001 | DPP-4 (Matched to Empagliflozin) - Japan | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 (DPP-4) between May 2014 and December 2019, in all countries included in this study. DPP-4 users were matched to incident users of empagliflozin, using a 1:1 propensity score matching approach. Only japanese patients are included in this arm. |
|
| Secondary | Total Healthcare Cost - South Korea | Total healthcare costs include costs for emergency room visits, first inpatient stay, all-cause hospital admissions, outpatient healthcare visits and pharmacy dispensations/prescriptions of different antidiabetic drugs, different drugs and prescriptions. Total healthcare costs for South Korea are reported in 1000 Korean Won (KRW) per year. Due to possible huge differences in healthcare systems, cost of care outcomes are presented by country as prespecified in the analysis plan. | Only patients who were included in the matched cohort of empagliflozin/DPP-4i from South Korea. Cost are presented descriptively by country as per prespecified analysis plan. | Posted | | Median | Inter-Quartile Range | 1000 KRW per year | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4) - South Korea | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, in all countries included in this study. Empagliflozin users were matched to incident users of (dipeptidyl peptidase-4) DPP-4 using a 1:1 propensity score matching approach. Only south-korean patients are included in this arm. | | OG001 | DPP-4 (Matched to Empagliflozin) - South Korea | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 (DPP-4) between May 2014 and December 2019, in all countries included in this study. DPP-4 users were matched to incident users of empagliflozin, using a 1:1 propensity score matching approach. Only south-korean patients are included in this arm. |
|
| Secondary | Total Healthcare Cost - Taiwan | Total healthcare costs include costs for emergency room visits, first inpatient stay, all-cause hospital admissions, outpatient healthcare visits and pharmacy dispensations/prescriptions of different antidiabetic drugs, different drugs and prescriptions. Total healthcare cost for Taiwan are reported in United States Dollar (USD) per year. Due to possible huge differences in healthcare systems, cost of care outcomes are presented by country as prespecified in the analysis plan. | Only patients who were included in the matched cohort of empagliflozin/DPP-4i from Taiwan. Costs are presented descriptively by country as per prespecified analysis plan. | Posted | | Median | Inter-Quartile Range | USD per year | | From index date until end of follow-up, up to 67 months. | | | | ID | Title | Description |
|---|
| OG000 | Empagliflozin (Matched to DPP-4) - Taiwan | Patients with type 2 diabetes mellitus (T2DM), who were new users of empagliflozin between May 2014 and December 2019, in all countries included in this study. Empagliflozin users were matched to incident users of (dipeptidyl peptidase-4) DPP-4 using a 1:1 propensity score matching approach. Only taiwanese patients are included in this arm. | | OG001 | DPP-4 (Matched to Empagliflozin) - Taiwan | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 (DPP-4) between May 2014 and December 2019, in all countries included in this study. DPP-4 users were matched to incident users of empagliflozin, using a 1:1 propensity score matching approach. Only taiwanese patients are included in this arm. |
|